IMVT
Income statement / Annual
Last year (2025), Immunovant, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Immunovant, Inc.'s net income was -$413.84 M.
See Immunovant, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$21.00 K
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$21.00 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$360.92 M
|
$212.93 M
|
$160.26 M
|
$101.81 M
|
$68.60 M
|
$47.93 M
|
$25.73 M
|
$135.26 M
|
| General & Administrative Expenses |
$77.24 M
|
$57.28 M
|
$48.02 M
|
$54.23 M
|
$39.51 M
|
$0.00
|
$2.69 M
|
$1.48 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.69 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$77.24 M
|
$57.28 M
|
$48.02 M
|
$54.23 M
|
$39.51 M
|
$11.73 M
|
$448.00
|
$1.48 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$438.15 M
|
$270.21 M
|
$208.28 M
|
$156.03 M
|
$108.12 M
|
$59.66 M
|
$448.00
|
$136.74 M
|
| Cost And Expenses |
$438.15 M
|
$270.21 M
|
$208.28 M
|
$156.03 M
|
$108.12 M
|
$59.68 M
|
$448.00
|
$136.74 M
|
| Interest Income |
$24.73 M
|
$24.95 M
|
$7.58 M
|
$0.00
|
$0.00
|
$625.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$12.48 M
|
$0.00
|
$0.00
|
$625.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$377.00 K
|
$231.00 K
|
$193.00 K
|
$126.00 K
|
$65.00 K
|
$21.00 K
|
$10.00 K
|
$136.74 M
|
| EBITDA |
-$437.78 M |
-$269.98 M |
-$208.08 M |
-$155.91 M |
-$108.05 M |
-$65.65 M |
$9.55 K |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$25.20 M
|
$11.44 M
|
-$2.68 M
|
-$781.00 K
|
$328.00 K
|
-$6.61 M
|
$0.00
|
$116.00
|
| Income Before Tax |
-$412.95 M
|
-$258.77 M
|
-$210.95 M
|
-$156.81 M
|
-$107.79 M
|
-$66.29 M
|
-$448.00
|
-$136.74 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$891.00 K
|
$567.00 K
|
$9.00 K
|
-$84.00 K
|
-$358.00 K
|
$97.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$413.84 M
|
-$259.34 M
|
-$210.96 M
|
-$156.73 M
|
-$107.43 M
|
-$66.39 M
|
-$448.00
|
-$136.74 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.73 |
-1.88 |
-1.71 |
-1.43 |
-1.22 |
-1.54 |
-3.11652E-5 |
-13.68 |
| EPS Diluted |
-2.73 |
-1.88 |
-1.71 |
-1.43 |
-1.22 |
-1.54 |
-3.11652E-5 |
-13.67 |
| Weighted Average Shares Out |
$151.57 M
|
$138.10 M
|
$123.08 M
|
$109.68 M
|
$87.76 M
|
$43.20 M
|
$14.38 M
|
$10.00 M
|
| Weighted Average Shares Out Diluted |
$151.57 M
|
$138.10 M
|
$123.08 M
|
$109.68 M
|
$87.76 M
|
$43.20 M
|
$14.38 M
|
$10.00 M
|
| Link |
|
|
|
|
|
|
|
|
